When your research has the potential to save lives, you deserve a laboratory partner with the oncology pharmacology knowledge, breadth of tools and experience to help move life-changing drug candidates through preclinical development and beyond quickly and effectively.
Our discovery oncology solutions consist of in vitro and in vivo pharmacology efficacy models, in vivo imaging technologies, ex vivo assessments and focal radiation capabilities to support your oncology research programs. Our team helps you explore the effects of drugs and biologics using both human and syngeneic tumor models. This approach delivers decision-driving data to help advance your drug candidate toward the next cancer research breakthrough
Explore our comprehensive list of oncological cell lines.
Take advantage of the widest breadth of analysis tools and models in the industry.
Advance personalized medicine approaches with our patient-derived xenografts models
Access a full suite of molecular and cellular biology assays as well as advanced tissue analytics.
For over a decade, we have offered an industry-leading array of technology platforms to deliver efficient quality results:
Model & Tech Spotlights
View in-depth analysis, including growth curves and treatment response, for preclinical tumor models and technology in our model and tech spotlights.
NOW AVAILABLE
Improve your therapeutic efficacy predictions with our fully characterized patient-derived xenografts (PDX) representing multiple histotypes.
With a broad range of disseminated and subcutaneous tumor models characterized in NSG mice, and a scientific team that knows how to apply them, we can guide selection of the right tumor model for your Chimeric Antigen Receptor (CAR) T-cell study or other ACT study.
Fast Track Discovery Program
Expedite your candidate selection with quick start times, expert scientific collaboration and innovative science.
To understand how anticancer therapeutics behave in patients, we need preclinical oncology models that mimic actual human tissue. Reduce the failure rate of your candidate anticancer trials with our advances in tumor-specific 3D
Key considerations include selecting appropriate cell lines or animal models, determining dosing regimens, choosing relevant endpoints and accounting for potential drug resistance mechanisms. Labcorp's experienced scientists can provide guidance on study design for robust and translatable results.
Biomarkers help identify patient populations most likely to respond to a therapy, monitor treatment efficacy and provide insights into mechanisms of action and resistance. Labcorp's biomarker discovery and validation services support the development of companion diagnostics and personalized medicine approaches.
PDX models, which involve implanting human tumor samples into immunodeficient mice, are used to better represent human tumor biology and predict clinical responses to potential therapies. Labcorp maintains a large collection of well-characterized PDX models and offers customized PDX studies to support oncology drug discovery programs.
